VitaDAO, a collective for community-governed drug development focusing on longevity research, launched VITA-FAST tokens which allow token holders to influence longevity research directly. Token holders can decide on intellectual property licensing, set experiment priorities, and govern research on autophagy.

The initial token sale was oversubscribed by 2,000% with USD 620,000 in bids, demonstrating the public's eagerness to participate in scientific research.

As of June 2023, VitaDAO has amassed over 9,000 enthusiasts, researchers, and contributors utilizing its platform. Additionally, the organization has distributed more than USD 4 million in funding to 17+ projects, which focus on researching the diseases of aging, with a particular emphasis on cellular biology and the repair of damage associated with the hallmarks of aging.

Analyst QuickTake: This January, VitaDAO raised USD 4.1 million in a strategic funding round . The funds were earmarked toward investing in longevity research projects, preceding the spinout of VitaDAO’s first biotech startups scheduled in Q1 2023, and commercializing and licensing its IP-NFT assets through its Molecule DAO partnership.